Edition:
United States

Synthetic Biologics Inc (SYN.A)

SYN.A on American Stock Exchange

0.64USD
18 Aug 2017
Change (% chg)

$0.05 (+8.88%)
Prev Close
$0.59
Open
$0.59
Day's High
$0.65
Day's Low
$0.58
Volume
160,927
Avg. Vol
149,558
52-wk High
$1.89
52-wk Low
$0.41

SYN.A

Chart for SYN.A

About

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $82.36
Shares Outstanding(Mil.): 128.25
Dividend: --
Yield (%): --

Financials

  SYN.A Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -0.17 -- --
ROI: -470.16 2.83 14.89
ROE: -500.53 5.09 16.13

BRIEF-Synthetic Biologics reports qtrly loss per share $‍0.03​

* Synthetic Biologics reports second quarter 2017 operational highlights and financial results

Aug 03 2017

BRIEF-Synthetic Biologics announces allowance of U.S. Patent covering Syn-010

* Synthetic Biologics announces allowance of key U.S. Patent covering Syn-010 intended for the novel treatment of irritable bowel syndrome with constipation (IBS-C)

Jun 27 2017

BRIEF-Synthetic Biologics receives FDA breakthrough therapy designation for SYN-004

* SYN-004 (ribaxamase) receives breakthrough therapy designation from U.S. Food and Drug Administration for prevention of clostridium difficile infection

May 11 2017

BRIEF-Synthetic Biologics qtrly loss per share $0.02

* Qtrly loss per share $0.02 Source text for Eikon: Further company coverage:

May 04 2017

BRIEF-Synthetic Biologics reports preclinical data on SYN-005

* Synthetic Biologics reports preclinical data demonstrating SYN-005 provides protection from Pertussis in neonatal animal study Source text for Eikon: Further company coverage:

Apr 19 2017

Earnings vs. Estimates